BiCNU Alternatives Compared
| BiCNU (carmustine) | Abecma (idecabtagene vicleucel) | Carvykti (ciltacabtagene autoleucel) |
|
|---|
| BiCNU (carmustine) | Abecma (idecabtagene vicleucel) | Carvykti (ciltacabtagene autoleucel) |
|
|||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Prescribed for Glioblastoma Multiforme, Non-Hodgkin's Lymphoma, Brain Tumor, Hodgkin's Lymphoma, Malignant Glioma, Multiple Myeloma. BiCNU may also be used for purposes not listed in this medication guide. View more |
Prescription only
Prescribed for Multiple Myeloma. Abecma may also be used for purposes not listed in this medication guide. |
Prescription only
Prescribed for Multiple Myeloma. Carvykti may also be used for purposes not listed in this medication guide. |
Related suggestions Multiple Myeloma
|
|||||||||||||||
| More about BiCNU (carmustine) | More about Abecma (idecabtagene vicleucel) | More about Carvykti (ciltacabtagene autoleucel) | ||||||||||||||||
| Ratings & Reviews | ||||||||||||||||||
|
Be the first to share your experience with this drug. |
Be the first to share your experience with this drug. |
Be the first to share your experience with this drug. |
||||||||||||||||
| Side Effects Experienced by Users Side effects are reported in Drugs.com user reviews and not clinically verified. | ||||||||||||||||||
|
View all BiCNU side effects |
View all Abecma side effects |
View all Carvykti side effects |
||||||||||||||||
| Drug Class | ||||||||||||||||||
| Generic Availability | ||||||||||||||||||
|
N/A |
N/A |
|||||||||||||||||
| Pricing and Coupons * Prices are without insurance | ||||||||||||||||||
|
We could not find an exact match for this medicine. Try searching the Price Guide directly. |
View all Abecma prices |
View all Carvykti prices |
||||||||||||||||
| Dosage Forms | ||||||||||||||||||
|
|
|
||||||||||||||||
| Brand Names | ||||||||||||||||||
| Other carmustine brands include: Gliadel |
N/A |
N/A |
||||||||||||||||
| Half Life Drug half-life is the time required for plasma concentration to reduce to half its original value. | ||||||||||||||||||
|
67 hours |
N/A |
N/A |
||||||||||||||||
| CSA Schedule 1 View glossary of CSA terms | ||||||||||||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||
| Pregnancy Category | ||||||||||||||||||
|
Category D
Positive evidence of risk
See the full pregnancy warnings document. |
Summary unavailable. See the full pregnancy warnings document. |
Summary unavailable. See the full pregnancy warnings document. |
||||||||||||||||
| Drug Interactions | ||||||||||||||||||
|
A total of 279 drugs are known to interact with BiCNU:
|
A total of 293 drugs are known to interact with Abecma:
|
A total of 303 drugs are known to interact with Carvykti:
|
||||||||||||||||
| Alcohol/Food/Lifestyle Interactions | ||||||||||||||||||
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
||||||||||||||||
| Disease Interactions | ||||||||||||||||||
| First Approval Date | ||||||||||||||||||
|
March 07, 1977 |
N/A |
N/A |
||||||||||||||||
| WADA Class View classifications | ||||||||||||||||||
|
N/A |
N/A |
N/A |
||||||||||||||||
| More Information | ||||||||||||||||||
| Patient Resources | ||||||||||||||||||
| Professional Resources | ||||||||||||||||||
| Related Treatment Guide | ||||||||||||||||||
1 The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.